Due to the high specificity of BCR-ABL1, its detection is mandatory for diagnosis of CML and is further underscored by the influence on therapy with the small molecule tyrosine kinase inhibitor (TKI) Imatinib [4]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.